Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer?
| Autor: | Ricardo F. Sánchez-Ortiz, Kim Anh Do, Charles J. Rosser, Deborah A. Kuban, Rex Cheung, Xuemei Wang, Ashish M. Kamat, Ramsey Chichakli, Louis L. Pisters, Andrew K. Lee |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
Nephrology medicine.medical_specialty Urology medicine.medical_treatment urologic and male genital diseases Prostate cancer Internal medicine Biopsy medicine Humans External beam radiotherapy Aged Aged 80 and over medicine.diagnostic_test business.industry Proportional hazards model Age Factors Prostatic Neoplasms Middle Aged Prostate-Specific Antigen medicine.disease Surgery Radiation therapy Prostate-specific antigen T-stage business |
| Zdroj: | Urology. 66:327-331 |
| ISSN: | 0090-4295 |
| DOI: | 10.1016/j.urology.2005.02.026 |
| Popis: | Objectives To evaluate the effect of patient age on the occurrence of prostate-specific antigen (PSA) "bounce" after external beam radiotherapy (EBRT) for prostate cancer. Methods In this study, 964 patients received EBRT alone for prostate cancer between April 1987 and January 1998 who had been followed for at least 12 months. Prostate-specific antigen values were obtained every 3 to 6 months after radiotherapy. Median overall follow-up was 48 months. Prostate-specific antigen bounce was defined as an initial increase in serum PSA of at least 0.5 ng/mL, followed by a decrease to prebounce baseline serum PSA values, all within 60 months after EBRT. Biochemical failure was defined as three consecutive increases in posttreatment PSA concentration after achieving a nadir. Multivariate Cox regression analysis was performed to evaluate the influences of age, pretreatment PSA concentration, Gleason score (determined at biopsy), clinical T stage classification, and radiation dose on PSA bounce-free survival and biochemical disease-free survival, with P Results Twelve percent of the patients developed a PSA bounce. Age was not associated with the occurrence of a PSA bounce ( P = 0.63), the magnitude of the PSA bounce ( P = 0.90), or the duration of the PSA bounce ( P = 0.39). Patients who had PSA bounce had a statistically significant higher biochemical disease-free survival than those who did not ( P = 0.00004). Conclusions In our study, age was not predictive of PSA bounce. However, younger patients with a rising PSA after radiotherapy should be followed closely for evidence of biochemical failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect